Disitamab vedotin plus toripalimab nearly doubled progression-free and overall survival compared to chemotherapy in HER2-expressing la/mUC patients. The combination therapy showed a 64% reduction in ...

The PR.21 study found no significant difference in rPFS between 177Lu-PSMA-617 and docetaxel in mCRPC patients. 177Lu-PSMA-617 showed a higher PSA response rate compared to docetaxel, with 36% vs 16% ...

Belzutifan, pembrolizumab, and lenvatinib combination showed superior efficacy in advanced ccRCC, with high overall response ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...

The NIAGARA trial showed that adding durvalumab to neoadjuvant chemotherapy in MIBC patients did not negatively impact HRQOL outcomes. Significant improvement in event-free survival was observed with ...

The ARASAFE study showed significant reductions in grade 3-5 adverse events and grade 3-4 neutropenia or death with a 50 ...

Detalimogene voraplasmid is a non-viral gene therapy for high-risk NMIBC, aiming to elicit an anti-tumor immune response. The LEGEND trial's pivotal cohort has enrolled 100 patients, with updates ...

AI tools like PathomIQ can predict prostate cancer metastasis by analyzing whole-slide images, independent of Gleason scores and gene expression profiling. Current AI applications in prostate cancer ...

"As with all medications and services, it is important to check with the patient’s insurer to determine their policy and whether the medication will be covered," write Jonathan Rubenstein, MD, and ...

Paul E. Dato, MD, discusses how bone-targeted therapies play an important supportive role in advanced prostate cancer, with recommendations for calcium and vitamin D supplementation, vitamin K2 ...

The survey examines urologists' treatment patterns and preferences for non–muscle invasive bladder cancer, providing valuable insights into current practices. Michael S. Cookson, MD, and Jason M.